×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Formycon Reports 83% Revenue Increase in 2023
Center for Biosimilars®
Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7...
4 weeks ago
Settlement ends Formycon and Johnson & Johnson FYB202 biosimilar dispute
JUVE Patent
Settlement ends Formycon and Johnson & Johnson FYB202 biosimilar dispute. Formycon, Fresenius Kabi and Johnson & Johnson have reached an...
1 month ago
Formycon Believes Itself Among Frontrunners For Mammoth Keytruda Opportunity
Generics Bulletin
On the back of early success with its biosimilar to Lucentis (ranibizumab), Formycon has looked further into the future and divulged details on the...
1 month ago
We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability
Simply Wall Street
Formycon AG ( ETR:FYB ) recently released a strong earnings report, and the market responded by raising the share...
2 weeks ago
Gedeon Richter Becomes Strategic Investor of Formycon
CHEManager
The total inflow of funds, Formycon said, will be used primarily for the further development of its existing biosimilar pipeline, especially...
3 months ago
J&J's Stelara settlement streak rolls on with Fresenius Kabi, Formycon deal
Fierce Pharma
J&J has signed its latest Stelara patent settlement with Fresenius Kabi and Formycon, granting the biosimilar partners a U.S. license date for...
9 months ago
J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius
Pharmaceutical Technology
In May, J&J settled its patent lawsuit with Amgen, setting the biosimilar's launch to no later than 1 January 2025. A month later, J&J reached a...
9 months ago
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
Morningstar
By David Sachs. Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a...
2 months ago
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
sharewise
EQS-News: Formycon AG / Key word(s): Quarterly / Interim Statement/Quarter Results Formycon reports on successful operating business and...
2 weeks ago
Formycon Announces Health Canada Approval Of Ranibizumab Biosimilar
Generics Bulletin
Formycon has announced the approval of its biosimilar ranibizumab by Health Canada, with commercial launch by Teva expected to begin in Q1 next year.
1 month ago